anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a medical information management system, capable of managing a user's physical characteristic while allowing the user to refer to the physical characteristic and to set the propriety of disclosure thereof.  <P>SOLUTION: A physical characteristic information provision request means 11 transmits, upon receipt of a registration request of physical characteristic information with designation of a medical institution from a user terminal 40, a physical characteristic information providing request including a user ID to a corresponding medical institution terminal 50. A physical characteristic information registration means 12 registers the physical characteristic information provided from the medical institution terminal 50 which received the physical characteristic information providing request in a physical characteristic information database 20 in association with the user ID and a disclosure condition designated by the user. A physical characteristic information search means 13 searches for, upon receipt of a disclosure request of physical characteristic information with designation of a user from the medical institution terminal 50, the registered physical characteristic information from the database 20. A disclosure propriety determination means 14 determines the propriety of disclosure of the searched physical characteristic information based on the corresponding disclosure condition.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Closed loop drug perfusion system with synergistic control. The aim of the invention is to realize an automatic drug perfusion calculation system applicable to a patient in order, for example, to induce a satisfactory anesthetic state in a surgical procedure. The automatic calculation system would be conditioned by target values from physiological monitors to assess the patient's condition. Automatic perfusion increases patient safety by reducing post-intervention morbidity and mortality and reducing continuous decision-making by the specialist. The invention is an electronic system where a MIMO-PID controller is implemented that calculates the infusions of various drugs based on a control error defined by deviations in the patient's condition, analyzed by various monitors. Automatic drug infusions are conditioned by safety systems against under/over-infusion events and are complemented by correction and prefeeding systems. (Machine-translation by Google Translate, not legally binding)
PURPOSE:Keratolytics containing an anionic surfactant and another surfactant having N atoms in the molecule in combination, capable of cleaning the skin without damaging the skin, and removing the keratin with ease. CONSTITUTION:Keratolytics containing one or two or more anionic surfactants, e.g. sodium lauryl sulfate, and one or two or more other surfactants having nitrogen atoms in the molecule other than the anionic surfactants, e.g. lauryldemethylamine oxide, at preferably (20:1)-(1:20), preferably (10:1)-(1:10), molar ratio. The keratolytics have improved dissolving action on the keratinized tissee and a slight irritation to the skin. Therefore, the agent is used directly or incorporated with various bases, e.g. a liquid, jelly, ointment or creamy base, for use.
Assessing the molecular profiles of bladder cancer (BC) from patients with locally advanced or metastatic disease provides valuable insights, such as identification of invasive markers, to guide personalized treatment. Currently, most molecular profiling of BC is based on highly invasive biopsy or transurethral tumor resection. Liquid biopsy takes advantage of less-invasive procedures to longitudinally profile disease. Circulating tumor cells (CTCs) isolated from blood are one of the key analytes of liquid biopsy. In this study, we developed a protein and mRNA co-analysis workflow for BC CTCs utilizing the graphene oxide (GO) microfluidic chip. The GO chip was conjugated with antibodies against both EpCAM and EGFR to isolate CTCs from 1 mL of blood drawn from BC patients. Following CTC capture, protein and mRNA were analyzed using immunofluorescent staining and ion-torrent-based whole transcriptome sequencing, respectively. Elevated CTC counts were significantly associated with patient disease status at the time of blood draw. We found a count greater than 2.5 CTCs per mL was associated with shorter overall survival. The invasive markers EGFR, HER2, CD31, and ADAM15 were detected in CTC subpopulations. Whole transcriptome sequencing showed distinct RNA expression profiles from patients with or without tumor burden at the time of blood draw. In patients with advanced metastatic disease, we found significant upregulation of metastasis-related and chemotherapy-resistant genes. This methodology demonstrates the capability of GO chip-based assays to identify tumor-related RNA signatures, highlighting the prognostic potential of CTCs in metastatic BC patients.
Oxidative stress refers to the imbalance between the production of reactive oxygen species (ROS) and the endogenous antioxidant defense system. Its involvement in cell senescence, apoptosis, and series diseases has been demonstrated. Advances in carcinogenic research have revealed oxidative stress as a pivotal pathophysiological pathway in tumorigenesis and to be involved in lung cancer, glioma, hepatocellular carcinoma, leukemia, and so on. This review combs the effects of oxidative stress on tumorigenesis on each phase and cell fate determination, and three features are discussed. Oxidative stress takes part in the processes ranging from tumorigenesis to tumor death via series pathways and processes like mitochondrial stress, endoplasmic reticulum stress, and ferroptosis. It can affect cell fate by engaging in the complex relationships between senescence, death, and cancer. The influence of oxidative stress on tumorigenesis and progression is a multi-stage interlaced process that includes two aspects of promotion and inhibition, with mitochondria as the core of regulation. A deeper and more comprehensive understanding of the effects of oxidative stress on tumorigenesis is conducive to exploring more tumor therapies.
Age-related physical and cognitive decline, as well as the risk of neurological diseases, are increased by the effects of psychosocial stress. Psychosocial stress triggers neuroendocrine, metabolic, cardiovascular, and inflammatory changes in the body. These changes vary in nature and magnitude between individuals, and are associated with long-term disease risk. However, the biological determinants of the stress response are not well understood.

This project aims to translate the preclinical findings (how mitochondria regulate the different organ systems and major stress response axes are activated during psychological stress) by studying a population of individuals with varying degree of mitochondrial dysfunction, and to test potential neural mechanism, and why some individuals respond more strongly than others to the same stressor.

Each participant will be studied over two consecutive days. Participants will be housed on campus to standardize study conditions. On Day 1, participants will donate blood and saliva, undergo a neuropsychological assessment, and complete questionnaires to assess psychosocial functioning and psychiatric symptoms. After lunch, the investigator will monitor dynamic changes in mental health-related biological outcomes (positive and negative affect, circulating levels of the inflammatory cytokine IL-6, and salivary cortisol) in response to a standardized laboratory challenge. On Day 2, participants will undergo a medical evaluation to assess clinical symptoms and undergo a whole brain neuroimaging session where both resting and stress elicited activity will be measured. A variant of the same stressor as on Day 1 will be used in the neuroimaging session. Participants will then be debriefed, concluding the individuals participation in the study. Participants also complete a home-based saliva and stool collection to examine diurnal variation in salivary hormones, and to examine microbiome composition. This translational project will generate a unique combination of complimentary molecular, cellular, and neuroimaging data that will advance our understanding of the links between mitochondria, the brain, and mental health-related outcomes.
Objective: To investigate the differences in resting-state functional connectivity (FC) between patients with vestibular migraine (VM) and migraine without aura (MwoA) in order to infer the possible neuroimaging mechanisms of VM. Methods: Thirty VM patients admitted to the Department of Neurology of the Second Affiliated Hospital of Xuzhou Medical University from December 2019 to December 2022 were selected as the experimental group (EG) (6 males and 24 females, with mean age of 38.3 years) and 26 MwoA patients as the control group (7 males and 19 females, mean age 35.5 years). General demographic and clinical data such as gender, age, year of education, course of disease and frequency of attacks were collected for all the patients, as well as data of Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), Montreal Cognitive Assessment (MoCA), headache Visual Arialogue Scale (VAS), Headache Impact Test 6 (HIT-6) and Migraine Disability Assessment Questionnaire (MIDAS). VM patients were also assessed by Dizziness Handicap Inventory (DHI), dizziness VAS and Vestibular Disorders Activities of Daily Living (VADL) scales. All patients underwent resting-sate functional Magnetic Resonance Imaging (fMRI) scans. Bilateral parietal opercular cortex 2 (OP2) and primary visual cortex (V1) were used as regions of interests (ROIs). Differences in FC between ROIs and other brain regions were calculated between the two groups. In view of the brain regions with significant differences, z-values of FC were extracted for each subject in the EG, and Pearson partial correlation analysis was conducted between z-values of FC and clinical characteristics of patients, P<0.05 was considered to have significant correlation. SPSS 22.0 was used for statistical analysis. Results: There was no significant difference in gender, age, years of education, course of disease, frequency of attack and scores of MoCA, HAMA and HAMD between the two groups (P>0.05). Headache VAS, HIT-6 and MIDAS scores in VM patients were significantly lower than those in MwoA patients (P<0.05). Compared with MwoA patients, the FC between left OP2 and bilateral precuneus and left thalamus was significantly increased in VM patients, and the FC between right OP2 and left thalamus and right anterior cingulate gyrus were significantly increased (P<0.05, False Discovery Rate correction). Correlation analysis showed that the FC between left OP2 and left precuneus was positively correlated with DHI score in VM patients (P=0.007, r=0.480), and the FC between right OP2 and left thalamus was positively correlated with the disease course in VM patients (P=0.015, r=0.439). Conclusions: The pathogenesis of VM may be related to the altered FC of vestibular, pain and visual-motor networks, abnormalities of these neural pathways may be important imaging biomarkers of VM pathogenesis.
PURPOSE:To provide the titled medicine, by adding fly ash to granular crystalline ferrous sulfate heptahydrate, heating, stirring and drying the mixture, and finely pulverizing the obtained powdery mixture. CONSTITUTION:80pts.wt. of coarse crystals of ferrous sulfate heptahydrate is mixed with 10-20pts.wt. of fly ash (various inorganic oxides activated with high temperature and containing P, Ca, Mg, K, Na, etc. as minor components), and the mixture is stirred and dried at 65-80 deg.C for 1hr. The crystal of the ferrous sulfate is spontaneously disintegrated evolving a part of the water of crystallization, and at the same time, fine fly ash powder is attached to the surface of the disintegrated crystal particles to lower the absorptivity of ferrous sulfate and improve the flowability of the particles. Inorganic powder mutually neutralized to weakly alkaline state can be obtained by this process. The powder is used as a component of the objective tonic medicine for improving the constitution of the human body. EFFECT:There is absolutely no side effects even by the continous administration for a long period. The raw material is industrial by-product or waste available at a low cost, and the preparation process of the medicine is simple.
Clinical studies have demonstrated that elevated levels of total-C, LDL-C and Apo B, the major protein constituent of LDL, promote human atherosclerosis. In addition, decreased levels of HDL-C are associated with the development of atherosclerosis. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis. The independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.

Atorvastatin as well as some of its metabolites are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see Dosage and Administration (2)].
The invention relates to a novel process for the preparation of stable complex multiple emulsions of the water-oil-water type which are well suited for use in cosmetic preparations. The primary emulsions of the W/O type are prepared in the presence of both a non-ionic polymeric lipophilic emulsifier and a non-ionic polymeric stabiliser each preferably having an HLB value in the range from 6 to 10. In a second process step more water containing a hydrophilic emulsifier having a higher HLB value, preferably in the range from 12 to 25, is added to the primary emulsion until phase inversion occurs. It is important that the procedure in this second process step is not reversed, i.e. that the primary emulsion is not added to the aqueous phase. Further active substances, such as UV filters and vitamins, may be added to the aqueous or oil phase respectively. In a third process step hydrating agents and/or gelling agents may be added, thus increasing the viscosity without impairing the stability of the multiple emulsion.
Deregulated centrosome numbers are frequently found in human cancer and can promote malignancies in model organisms. Current research aims to clarify if extra centrosomes are cause or consequence of malignant transformation, and if their biogenesis can be targeted for therapy. Here, we show that oncogene-driven blood cancer is inert to genetic manipulation of centrosome numbers, whereas the formation of DNA damage-induced malignancies is delayed. We provide first evidence that this unexpected phenomenon is connected to extra centrosomes eliciting a pro-death signal engaging the apoptotic machinery. Apoptosis induction requires the PIDDosome multi-protein complex, as it can be abrogated by loss of any of its three components, Caspase-2, Raidd/Cradd, or Pidd1. BCL2 overexpression equally blocks cell death, documenting for the first time induction of mitochondrial apoptosis downstream of extra centrosomes. Our findings demonstrate context-dependent effects of centrosome amplification during transformation and ask to adjust current belief that extra centrosomes are intrinsically pro-tumorigenic.
A method for preventing or treating restenosis and for preventing the recurrence or progression of coronary heart disease is provided. The method involves administration of a selected active agent to a patient following coronary intervention, e.g., coronary artery bypass surgery, endarterectomy, heart transplantation, heart balloon angioplasty, atherectomy, laser ablation or endovascular stending. The active agent comprises cis-resveratrol, a mixture thereof, or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof. Administration may be oral, parenteral, or the like. Pharmaceutical compositions for use in conjunction with the therapeutic method are also provided. <IMAGE>
When taking Cyred EQ®, the first white to off-white “active” tablet should be taken on the first Sunday after menstruation begins. If the period begins on Sunday, the first white to off-white “active” tablet is taken on that day. If switching directly from another oral contraceptive, the first white to off-white “active” tablet should be taken on the first Sunday after the last ACTIVE tablet of the previous product. Tablets are taken without interruption as follows: One white to off-white “active” tablet daily for 21 days, then one green “reminder” tablet daily for 7 days. After 28 tablets have been taken, a new course is started and a white to off-white “active” tablet is taken the next day (Sunday). When initiating a Sunday start regimen, another method of contraception should be used until after the first 7 consecutive days of administration.  
  
The use of Cyred EQ® for contraception may be initiated 4 weeks postpartum. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered. (See CONTRAINDICATIONS and WARNINGS concerning thromboembolic disease. See also PRECAUTIONS: Nursing Mothers.) If the patient starts on Cyred EQ® postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a white to off-white “active” tablet has been taken daily for 7 days. The possibility of ovulation and conception prior to initiation of medication should be considered. If the patient misses one (1) white to off-white active tablet in Weeks 1, 2, or 3, the white to off-white “active” tablet should be taken as soon as she remembers. If the patient misses two (2) white to off-white “active” tablets in Week 1 or Week 2, the patient should take two (2) white to off-white “active” tablets the day she remembers and two (2) white to off-white “active” tablets the next day; and then continue taking one (1) white to off-white “active” tablet a day until she finishes the pack. The patient should be instructed to use a back-up method of birth control such as a condom or spermicide if she has sex in the seven (7) days after missing pills. If the patient misses two (2) white to off-white “active” tablets in the third week or misses three (3) or more white to off-white “active” tablets in a row, the patient should continue taking one white to off-white “active” tablet every day until Sunday. On Sunday the patient should throw out the rest of the pack and start a new pack that same day. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills.
Participants will brush their teeth using marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute, floss with Reach Unflavored Waxed Dental Floss and rinse with LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 seconds under virtual supervision once daily during the week. At home, participants will brush and rinse a second time unsupervised daily in the evening. Over weekends and holidays, participants will brush, floss and rinse once daily. Only brushing and rinsing will be performed a second time in the evening for 12 weeks. First product use will occur at the site under supervision.
The invention relates to a cosmetic cream facepack with 10-40% dried marine silt. The cream base of the facepack can be both an oil-in-water cream and a water-in-oil cream. Correct choice of the marine silt is important, and it ought to have as many as possible uniform mineral particles of 50-100  mu m with edges and sharp points worn down through the ages and by the action of waves. To produce the cream facepack, the dry silt is, after emulsification of the cream base, introduced into the still hot emulsion and subsequently stirred until cold. The facepack is used for care and massage of, for example, the facial skin and thereby for removing the dead cells on the surface of the skin. At the same time there is a cosmetic effect due to the constituents of the silt introduced with the dry silt.
Systems and methods relating to the assessment of risks for a user relative to conditions and/or disorders. A system provides a user with a questionnaire and, based on the user responses, the user's risk for psychological conditions is assessed or estimated. If the user is at risk for any of such conditions or disorders, the severity of the risk of these disorders is assessed and a database of professional specialists is consulted. Based on the severity of the risk for these disorders, one or more professional specialists are selected based on their availability and/or fields of specialty. The user can then select one or more of these professional specialists and, once selected, the user can then arrange for a session with a selected professional specialist. The session can be conducted using the systems communications module. The system of the invention can be incorporated into a larger health care monitoring/wellness provision service.
Post-stroke depression (PSD) is regarded as the consequence of multiple contributors involving the process of cognition, mood and autonomic system, with the specific mechanism unclear yet. As a common type of stroke-heart syndromes, post-stroke arrhythmia shared some common pathogenesis with PSD. We presumed that post-stroke arrhythmia might be an early distinguishable marker for the presence of PSD and aimed to verity their association in this study. Patients with first-ever ischemic stroke were enrolled. The presence of post-stroke ectopic arrhythmia and the symptoms of arrhythmia were recorded with anti-arrhythmia drugs prescribed when necessary. Patients were followed up 3 months later to identify their presence and severity of PSD using Hamilton Depression Scale (HAMD) and also presence and severity of arrhythmia. Characteristics including the prevalence of various types of arrhythmias were compared between PSD and non-PSD groups. The HAMD scores were compared between patients with and without arrhythmia in PSD group. Logistic regression was used to identify the independent predictor of PSD. Patients with PSD had higher prevalence of post-stroke arrhythmia especially newly-detected arrhythmia, symptomatic arrhythmia and poor-controlled arrhythmia. In PSD group, patients of post-stroke arrhythmia had higher scores of HAMD than those without arrhythmia. Presence of newly-detected, symptomatic and poor-controlled arrhythmias were independent predictor of PSD. post-stroke arrhythmia especially newly-detected arrhythmia and symptomatic arrhythmia could be an early predictor of PSD. Successful control of arrhythmia was associated with reduced prevalence and severity of PSD.